Fecal microbiota

Fecal microbiota, sold under the brand name, Rebyota is used for the prevention of recurrence of Clostridioides difficile infection.

The most commonly reported adverse reactions include abdominal pain, diarrhea, abdominal distention, flatulence, and nausea.

Fecal microbiota is prepared from stool donated by qualified individuals. The donors and the donated stool are tested for a panel of transmissible pathogens. Fecal microbiota is the first fecal microbiota product approved by the US Food and Drug Administration (FDA). Fecal microbiota was approved for medical use in the United States in November 2022.